Literature DB >> 16556847

Synergistic antitumor effects of immune cell-viral biotherapy.

Steve H Thorne1, Robert S Negrin, Christopher H Contag.   

Abstract

Targeted biological therapies hold tremendous potential for treatment of cancer, yet their use has been limited by constraints on delivery and effective tumor targeting. We combined an immune effector cell population [cytokine-induced killer (CIK) cells] with an oncolytic viral therapy to achieve directed delivery to, and regression of, tumors in both immunodeficient and immunocompetent mouse models. Preinfection of CIK cells with modified vaccinia virus resulted in a prolonged eclipse phase with the virus remaining hidden until interaction with the tumor. Whole-body imaging revealed that the cells retained their ability to traffic to and to infiltrate the tumor effectively before releasing the virus. These results illustrate the potential of combining biotherapeutics for synergistic effects that more effectively treat cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556847     DOI: 10.1126/science.1121411

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  112 in total

1.  IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.

Authors:  Mike W Helms; Jennifer A Prescher; Yu-An Cao; Steven Schaffert; Christopher H Contag
Journal:  Cancer Immunol Immunother       Date:  2010-06-09       Impact factor: 6.968

2.  Quantitative analysis of cell tracing by in vivo imaging system.

Authors:  Junmeng Zheng; Lijun Xu; Hongmin Zhou; Weina Zhang; Zhonghua Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-08-17

3.  Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Authors:  Liang-Chuan S Wang; Rachel C Lynn; Guanjun Cheng; Edward Alexander; Veena Kapoor; Edmund K Moon; Jing Sun; Zvi G Fridlender; Stuart N Isaacs; Stephen H Thorne; Steven M Albelda
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

4.  Oncolytic Poxviruses.

Authors:  Winnie M Chan; Grant McFadden
Journal:  Annu Rev Virol       Date:  2014-09-01       Impact factor: 10.431

Review 5.  The status of gene therapy for brain tumors.

Authors:  Giulia Fulci; E Antonio Chiocca
Journal:  Expert Opin Biol Ther       Date:  2007-02       Impact factor: 4.388

6.  Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells.

Authors:  Henry Ogbomo; Martin Michaelis; Janina Geiler; Marijke van Rikxoort; Thomas Muster; Andrej Egorov; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Med Microbiol Immunol       Date:  2009-12-15       Impact factor: 3.402

7.  In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.

Authors:  Ryosei Nishimura; Jeanette Baker; Andreas Beilhack; Robert Zeiser; Janelle A Olson; Emanuela I Sega; Mobin Karimi; Robert S Negrin
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

8.  Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Authors:  Padma Sampath; Jun Li; Weizhou Hou; Hannah Chen; David L Bartlett; Steve H Thorne
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

9.  Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Authors:  Ta-Chiang Liu; Pedro Castelo-Branco; Samuel D Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

10.  Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy.

Authors:  Samuel Eisenstein; Brian A Coakley; Karen Briley-Saebo; Ge Ma; Hui-Ming Chen; Marcia Meseck; Stephen Ward; Celia Divino; Savio Woo; Shu-Hsia Chen; Ping-Ying Pan
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.